Patents Examined by Lance Rider
  • Patent number: 9504761
    Abstract: A stabilized chitosan-based nanoparticle is provided having a chitosan polymer and a hydrophilic dispersing agent. In the stabilized nanoparticle, chains of the chitosan polymer electrostatically interact with chains of the hydrophilic dispersing agent to form an entangled network between the chitosan polymer and the hydrophilic dispersing agent. The stabilized chitosan-based nanoparticle has optimal particle integrity and stability properties under physiological conditions.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: November 29, 2016
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Swadeshmukul Santra, James Turkson, Astha Malhotra, Padmavathy Tallury
  • Patent number: 9499553
    Abstract: The present invention provides a dihydropyridazine-3,5-dione derivative or a salt thereof, or a solvate of the compound or the salt, a pharmaceutical drug, a pharmaceutical composition, a sodium-dependent phosphate transporter inhibitor, and a preventive and/or therapeutic agent for hyperphosphatemia, secondary hyperparathyroidism, chronic renal failure, chronic kidney disease, and arteriosclerosis associated with vascular calcification comprising the compound as an active ingredient, and a method for prevention and/or treatment.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: November 22, 2016
    Inventors: Yoshihito Ohtake, Naoki Okamoto, Yoshiyuki Ono, Hirotaka Kashiwagi, Atsushi Kimbara, Takeo Harada, Nobuyuki Hori, Yoshihisa Murata, Kazutaka Tachibana, Shota Tanaka, Kenichi Nomura, Mitsuaki Ide, Eisaku Mizuguchi, Yasuhiro Ichida, Shuichi Ohtomo, Naoshi Horiba
  • Patent number: 9486446
    Abstract: The present invention provides an orally-disintegrating solid preparation comprising fine granules showing controlled release of a pharmaceutically active ingredient, wherein the outermost layer of the fine granules is coated with a coating layer comprising hydroxypropylmethylcellulose and low-substituted hydroxypropylcellulose and breakage of the fine granules during tableting is suppressed.
    Type: Grant
    Filed: December 27, 2007
    Date of Patent: November 8, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Takashi Kurasawa, Yasuko Watanabe, Yohko Akiyama
  • Patent number: 9474810
    Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.
    Type: Grant
    Filed: March 2, 2012
    Date of Patent: October 25, 2016
    Assignee: General Electric Company
    Inventors: Bruce Allan Hay, Daniel Eugene Meyer, Brian Christopher Bales, Michael Todd Luttrell
  • Patent number: 9468607
    Abstract: The present invention provides nanoparticles, methods of making the nanoparticles, and methods of using the nanoparticles to deliver therapeutic agents and/or imaging agents.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: October 18, 2016
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Dipanjan Pan
  • Patent number: 9469728
    Abstract: Disclosed herein are pH- and temperature-sensitive block copolymer with excellent safety and a method for preparing the same and a hydrogel and a drug carrier using the block copolymer. According to the present invention, the pH- and temperature-sensitive block copolymer comprises: obtained by copolymerization of: (a) polyethylene glycol-based compound (A); and (b) poly (?-amino ester)-based oligomer (B) or poly (amido amine)-based oligomer (C) or coupling of mixture (D) thereof. In order to control biodegradation rate, the block copolymer is mixed with poly (amido amine)-based oligomer instead of the poly (?-amino ester)-based oligomer and then coupling them.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: October 18, 2016
    Inventors: Doo Sung Lee, Minh Khanh Nguyen, Bong Sup Kim
  • Patent number: 9402802
    Abstract: The present invention relates to a composition for topical administration comprising an ascomycin and a carrier vehicle comprising means to retain water in the outer skin layer and means to hinder water evaporating from the skin.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: August 2, 2016
    Assignee: MEDA Pharma SARL
    Inventors: Katrin Kriwet, Dorothea Ledergerber, Jutta Riedl
  • Patent number: 9376540
    Abstract: Polymeric porous particles have a continuous solid phase and at least two sets of discrete pores that are isolated from each other within the continuous phase and that have different average sizes. One set of discrete pores has a larger average size than another set of discrete pores by at least 50%. At least one set of discrete pores is free of detectably different marker materials. There porous particles can be prepared using evaporative limited coalescence techniques with especially chosen discrete pore stabilizing hydrocolloids to protect the pores during formation and to provide the different average sizes.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: June 28, 2016
    Inventors: David Charles Boris, Teresa Joy Hosmer, Mridula Nair
  • Patent number: 9358310
    Abstract: The invention provides stabilized, biocompatible gold nanoparticles that are stabilized with material from epigallocatechin Gallate (EGCg), which is a polyphenols- or flavonoids-rich plant material that can be obtained from green tea. The EGCg is an antioxidant reducing agent derived from green tea. The gold nanoparticles of the invention can be radioactive or non radioactive and are formed via a simple room temperature fabrication method. In preferred embodiment method of making, an aqueous solution containing gold salts is provided. The aqueous solution is mixed with EGCg in a buffer, such as deionized water. The gold salts react to form biocompatible gold nanoparticles that are stabilized with a coating of EGCg. The thermodynamically feasible redox couple of AuCl4-/EGCg leading to the reduction of AuCl4- by EGCg to form gold nanoparticles. In another embodiment, pre-cooled gold salt and EGCg solutions form multi-layered EGCg coated particles.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: June 7, 2016
    Assignee: The Curators of the University of Missouri
    Inventors: Kattesh V. Katti, Raghuraman Kannan, Kativa K. Katti, Satish Kumar Nune, Cathy S. Cutler, Charles Caldwell, Ravi Shukla, Nripen Chanda, Ajit Zambre, Anandhi Upendran
  • Patent number: 9339450
    Abstract: The invention relates to a composition that can be subcutaneously or intradermally injected, comprising: a filling agent; and a fibroblast growth medium.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 17, 2016
    Inventors: Jean-Noel Thorel, Hugues Gatto
  • Patent number: 9339559
    Abstract: A contrast agent having a contrast protein have contrast properties and at least one targeting moiety, wherein the at least one targeting moiety is operatively linked to or incorporated within the contrast protein. Methods for targeting contrast agents and for preparing such agents are included.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: May 17, 2016
    Assignee: Georgia State University Research Foundation, Inc.
    Inventors: Jenny J. Yang, Zhi-Ren Liu
  • Patent number: 9304124
    Abstract: A ligand design allows compact nanoparticle materials, such as quantum dots (QDs), with excellent colloidal stability over a wide range of pH and under high salt concentrations. Self-assembled biomolecular conjugates with QDs can be obtained which are stable in biological environments. Energy transfer with these ligands is maximized by minimizing distances between QDs/nanoparticles and donors/acceptors directly attached to the ligands or assembled on their surfaces.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: April 5, 2016
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Igor L. Medintz, Kimihiro Susumu, Michael H. Stewart
  • Patent number: 9295736
    Abstract: The invention provides nanoparticles consisting of a polymer which is a metal chelating agent coated with a magnetic metal oxide, wherein at least one active agent is covalently bound to the polymer, said nanoparticles may optionally further comprise at least one active agent physically or covalently bound to the outer surface of the magnetic metal oxide. Pharmaceutical compositions comprising these nanoparticles may be used, inter alia, for detection and treatment of tumors and inflammations.
    Type: Grant
    Filed: September 24, 2008
    Date of Patent: March 29, 2016
    Assignees: Bar Ilan University, Henry Ford Health System
    Inventors: Shlomo Margel, Benny Perlstein, Chaya Brodie, Tom Mikkelsen
  • Patent number: 9289464
    Abstract: The present invention relates to a method for diagnosing and/or treating sodium-iodide symporter (NIS)-expressing primary carcinomas and metastases, preferably glandular carcinomas, in particular carcinomas of the thyroid, of the salivary gland, of the uterus and carcinomas of the breast, and to a pharmacological composition comprising substances which induce and/or increase the expression or function of the NIS symporter and, as a consequence, increase iodide uptake into the cells, and to corresponding uses. This can be used for an efficient tumor-specific radioiodide uptake in diagnosis and therapy of said carcinomas and metastases.
    Type: Grant
    Filed: June 18, 2003
    Date of Patent: March 22, 2016
    Inventor: Ulrich Loos
  • Patent number: 9216220
    Abstract: Provided herein are systems, methods, and compositions for polymer nanoparticles and polymer magnetic nanoparticles. More particularly, the polymer nanoparticles and polymer magnetic nanoparticles are temperature sensitive and responsive to a first temperature.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: December 22, 2015
    Inventors: Kytai T. Nguyen, Maham Rahimi, Soujanya Kona, Arthur H. Lin
  • Patent number: 9161996
    Abstract: The various embodiments herein provide a gold coated SPIONs with jagged surface. The gold coated SPIONs have a core and a shell. The core is a SPION molecule and the shell is a jagged gold layer. A non-uniform polymeric gap exists between the core and the shell. The embodiments also provide a method of producing the jagged gold coated SPIONs by mixing a colloidal dispersion of SPIONs with pH sensitive polymers. Adding a gold salt to the above mixture and reducing the gold salt to form jagged gold coated SPIONs.
    Type: Grant
    Filed: April 30, 2011
    Date of Patent: October 20, 2015
    Inventors: Morteza Mahmoudi, Mohammad Ali Shokrgozar
  • Patent number: 9149540
    Abstract: Disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein an amide bond is not used. The compound has chemical stability and adequate drug release rate in the living organism. Specifically disclosed is a polymer conjugate of folic acid or a folic acid derivative, wherein a substituent represented by formula (I) is bonded to a carboxy group of a block copolymer which is composed of a polyethylene glycol and a polymer having a carboxy group in a side chain, or a pharmacologically acceptable salt thereof. [In the formula, A represents a monocyclic or fused aromatic group; G represents an optionally substituted (C1-C6) alkylene group; Y represents a hydrogen atom or a substituent; and E represents a residue of folic acid or a folic acid derivative.
    Type: Grant
    Filed: April 28, 2009
    Date of Patent: October 6, 2015
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Takeshi Nakanishi, Kazuhisa Hara, Chieko Seno
  • Patent number: 9120031
    Abstract: Embodiments of the invention provide a composition of a particulate coformulation which includes particles containing an active substance and an additive, wherein each particle contains a relative additive concentration increasing radially outwards from a particle center to a particle surface along a finite gradient. In one example, the particle surface is an additive-rich surface without a distinct physical boundary between the particle center and the particle surface. The relative additive concentration may have a continuous rate of change across the finite gradient. In some examples, an active substance: additive ratio of the particle surface is sufficiently low to form a protective surface layer around the active substance. Generally, the particle surface is free of the active substance.
    Type: Grant
    Filed: July 17, 2006
    Date of Patent: September 1, 2015
    Inventors: Mazen H. Hanna, Peter York
  • Patent number: 9072799
    Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.
    Type: Grant
    Filed: October 31, 2008
    Date of Patent: July 7, 2015
    Assignee: The Invention Science Fund I, LLC
    Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, Jr.
  • Patent number: 9052442
    Abstract: The invention provides a cost-effective and in-situ method for applying an LbL coating onto a silicone hydrogel contact lens directly in a lens package. The resultant silicone hydrogel contact lens has a coating with good hydrophilicity, intactness and durability and also can be used directly from the lens package by a patient without washing and/or rising. In addition, the invention provides a packaging solution for in-situ coating of a silicone hydrogel contact lens in a lens package and an ophthalmic lens product.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: John Dallas Pruitt, Lynn Cook Winterton, Sai Ramamurthy Kumar, Dawn A. Smith